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A B S T R A C T
Purpose: We attempted to identify any parameter that could possibly lead to a successful 
treatment outcome after transurethral microwave thermotherapy.
Materials and Methods: Clinical parameters and treatm ent profiles of 292 patients were 
analyzed in a retrospective multicenter manner. Responder and nonresponder groups were identified 
according to a given definition.
Results: No statistically significant differences in baseline characteristics were found. Re­
sponders showed a 76% symptomatic improvement rate compared to 27% in nonresponders, and 
an 82% improvement rate in peak flow compared to a 5% decrease in nonresponders. Responders 
also showed a significantly greater increase in posttreatment PSA level and a significantly 
greater amount of energy released during treatment.
Conclusions: No baseline clinical parameter is capable of predicting treatm ent outcome.
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Microwave heating of the prostate is a fascinating ap­
proach to the treatment of voiding disturbances in patients 
with benign prostatic hyperplasia (BPH).1"3 There are 2 basic 
concepts: hyperthermia in which the prostatic temperature 
is not allowed to exceed 45C, and therm otherapy in which 
the target temperature is greater than 45C.4-5 A recent 
multicenter study showed that hypertherm ia seems likely 
to be ineffective in the treatm ent of BPH and, thus, not to 
be recommended.6
Thermotherapy applies high power microwave energy deep 
within the lateral pro static lobes. The results of transure­
thral microwave thermotherapy are promising. It is pre­
sumed that clinical benefit is achieved by a small decrease in 
adenoma volume and the destruction of certain specific cell 
types that have some role in the development of bladder 
outlet obstruction. The clinical improvement has been shown 
not to be due to a placebo effect or the result of the associated 
urethral instrumentation in randomized trials of transure­
thral microwave thermotherapy versus a sham procedure.3*7 
However, the criteria currently used for inclusion do not 
prevent a high variability in terms of clinical response to 
transurethral microwave thermotherapy and treatm ent out­
come is difficult to forecast in the individual patient.
Clinical experience has shown that significant improve­
ment of subjective and objective parameters of disease sever­
ity is achieved in a subgroup of treated patients/3»5»8 Patient 
parameters at entry and treatment parameters have been
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investigated in different series for possible correlation with 
treatm ent outcome. For patient selection, the specific type 
and grade of obstruction at screening were correlated signif­
icantly with the response rate in a multicenter European 
study.9 Analysis of different treatm ent parameters that are 
currently monitored during microwave treatm ent to date has 
failed to identify any difference between treatm ents leading 
to successful outcome and those producing no change for the 
individual patient. More recently, analysis of patients under­
going invasive thermometry of the prostate during treatm ent 
suggested a significant correlation between the amount of 
heat induced within the gland and flow rate improvement.10
We investigate further patient treatm ent profiles to iden­
tify any parameter tha t could possibly lead to a successful 
treatm ent outcome. Digital records of the microwave treat­
ments from a large series of patients undergoing microwave 
therapy at 17 different prostate centers worldwide constitute 
the material for the study.
PA TIEN TS AND M ETHODS
Data from BPH patients undergoing microwave thermo­
therapy at 17 different hospitals were collected. The same 
instrument and treatm ent software were used a t the various 
centers, and treatm ents were performed according to a com­
mon study protocol. Treatment was given on an ambulatory 
basis and the method has been described in detail previous­
ly.11 A representation of a treatm ent session, the position of 
the catheter and rectal probe, and a treatm ent profile are 
demonstrated in figure 1. During transurethral microwave 
thermotherapy the microwave energy is emitted to the pros­
tate resulting in heat. To prevent damage to urethral mucosa 
or the rectal wall, 1 thermal sensor is positioned in the 
treatm ent device and 3 sensors are placed in the rectal probe 
to monitor the urethral and rectal wall temperatures. When 
the maximum allowed temperature is detected by 1 of these 
sensors an alarm automatically interrupts the treatment. 
Therapy is resumed when the temperature decreases to a 
certain level.
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Screening consisted of a patient history with the Madsen- 
Iversen symptom score, physical examination with digital 
rectal examination of the prostate, hematology and blood 
chemistry studies, including prostate specific antigen (PSA) 
measurements, electrocardiography, chest x-ray, kidney and 
bladder ultrasound imaging or excretory urography, trans- 
re ctal ultrasound of the prostate and uroflowmetry (twice) 
with measurements of post-void residual volume using ultra­
sound. All patients studied were candidates for transurethral 
resection of the prostate and had a Madsen-Iversen symptom 
score of 8 or more, maximum flow rate 15 ml. per second or 
less and post-void residual volume 250 ml. or less. Patients 
were excluded from the trial because of an obstructive pros­
tatic middle lobe, complications of BPH, suspicion of prostate 
cancer, presence of any condition that could interfere with 
bladder dynamics and patient compliance to the protocol.
Each center was asked to provide case record forms and 
copies of the treatment computer files of at least 10 respond­
ers and 10 nonresponders to microwave thermotherapy. Re­
sponders were identified by a Madsen-Iversen symptom score 
of 3 or less, or 50% or greater decrease at month 6, a maxi­
mum flow rate of 15 ml. per second or more, or 50% or greater 
improvement and a post-void residual volume of 50 ml. or 
less or 50% or greater improvement at 6 months. Nonre­
sponders were identified by a Madsen-Iversen symptom score 
of 8 or more or 50% or less improvement, a maximum flow 
rate of 10 ml. per second or less, or 20% or less improvement, 
and a post-void residual volume of 200 ml. or more, or 50% or 
less decrease at 6 months. At each center data were derived 
from consecutive series of patients satisfying the described 
criteria.
Followup visits, including symptom evaluation by Madsen- 
Iversen symptom score, flow rate measurements by free flow 
uroflowmetry and residual urine measurement by ultra­
sound, were scheduled a t 1, 3 and 6 months after treatment. 
Blood samples were collected at selected sites at 1 day, and 
1 and 12 weeks after thermo therapy. Quality data control 
included survey of the received case record forms and 
treatm ent files. Only patients with complete data bases 
were considered evaluable for analysis. Data collected from 
case record forms and retrieved from treatment files were 
entered in a computer file and analyzed by a statistical 
program*
RESULTS
Of 292 patients evaluable for analysis 136 were responders 
and 156 were nonresponders. Analysis of patient parameters 
at screening showed no significant difference between the 2 
groups (table 1). Changes in Madsen-Iversen symptom score, 
maximum flow rate and post-void residual volume are pre­
sented in figure 2, Responders showed an average improve­
ment of 76% for Madsen-Iversen symptom score and an in­
crease in maximum flow rate of 82%, with a decrease of 37% 
in post-void residual volume (table 2). Nonresponders had an 
average decrease of 27% for symptom score, an actual de­
crease in flow rate of 5% and only a decrease of 14% in 
post-void residual volume.
Screening plasma levels of PSA were comparable between 
the 2 groups, Heat produced by microwave thermotherapy in 
the prostate gland is responsible for the observed increase in 
PSA level. Interestingly, at week 1 significantly higher val­
ues were measured in responders (+371%) compared to non­
responders (+176%). PSA values at 3 months were again 
comparable between the 2 groups and did not differ signifi­
cantly from baseline (fig. 3).
Different parameters derived from digital records of the 
microwave treatments were analyzed (fig. 4). The amount of 
energy released during treatment, measured as total energy 
dose, average dose and maximum power output, was signif­
icantly different in the 2 groups. The higher amount of en­
ergy released in the responder group resulted in a higher 
temperature at the level of the urethra. The number of ure­
thral alarms was greater in responders versus nonre­
sponders but the difference was not significant (fig. 5). Not­
withstanding a higher energy release in responders, 
temperatures recorded at the level of the rectal wall were 
comparable in the 2 groups. Nevertheless, fewer rectal 
alarms were observed in responders compared to nonre­
sponders.




Age (yrs.) 66.8 ± 7.9 66.4 ± 8,3
Prostate vol. (ml.) 45.0 ± 18,0 44.0 ± 18.0
Madsen score 13.7 ± 4.0 13.3 ± 4.3
Maximum flow rate (ml./sec.) 8.8 ± 3.7 8.3 ± 3.3
Post-void residual vol. (ml.) 96.0 ± 158.0 78.0 ± 80.0
PSA <ng./m!) 4.1 + 4.3 4,2 ± 3.3
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Fig. 2. Difference in symptom score, post-void residual volume, 
CPVR) and maximum flow rate (Qmax) between responders and 
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Fig. 4. Difference in maximum {Max) power, average power and 
total administered amount of energy between responders and non­
responders.
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T a b le  2. Values at baseline and at 6 months





Madsen score 13.7 ± 4.0 3.2 ±  3.3
Maximum flow rate (ml./sec,) 8.8 ± 3.7 16.0 ±  5.7
Post-void (ml.) 96.0 ± 158.0 35.0 ± 50.0
Nonresponders:
Madsen score 13.9 ± 4.2 9.6 ±  4.0
Maximum flow rate (ml./sec,) 8.3 ± 3.3 7,9 ±  3.0
Post-void (ml.) 78,0 ± 80.0 67.0 ± 77.0
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Fig. 3. Changes in PSA level (ng./ml.) between responders and 
nonresponders at baseline, and 1 day, 7 days and 3 months after 
treatment.
DISCUSSION
Variance analysis of data obtained has shown how our 
patient population did not differ significantly among the 
various sites and it is comparable with the BPH population 
enrolled in our previous studies. The use of 2 discrete popu­
lations of responders and nonresponders instead of a single 
group was designed to achieve a balance between the 2 groups, 
which is otherwise dependent on patient selection at the 
individual sites. Moreover, it is easier to perform such an 
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Fig. 5, Difference in number of rectal and urethral alarms be 
tween responders and nonresponders.
The outcome of thermotherapy has been shown previously 
to be variable between different sites.3»5’7’a-12 To identify 
selection criteria that could possibly predict successful trea t­
ment outcome, a large series of patients was evaluated ac­
cording to the response to treatment. Responder and nonre­
sponder characteristics at screening were not statistically 
different, which further supports a previous supposition from 
our group that currently only baseline urodynamic parame­
ters can predict clinical outcome from microwave treatm ent.9 
Provided the 2 groups of patients were comparable at base­
line, a different microwave treatm ent profile could have been 
responsible for the different outcome in the 2 populations. 
The treatm ent profile reflects the energy delivered to the 
prostate, and depends on the number of the rectal and ure­
thral alarms (fig. 1). The alarms result in a safe treatm ent 
but they may limit the emission of microwave energy. In view 
of the results achieved with higher energy levels, we believe 
tha t the safety of treatm ent obviously interferes with effi­
cacy. One cannot have high tem peratures within the prostate 
using low power levels.10 We know th a t the amount of heat 
produced within the prostate is correlated with objective 
clinical outcome but such parameters are not available in 
this series. Nevertheless, we still have an indirect measure of 
intraprostatic temperatures, which is given by the elevation 
of PSA on the days following transurethral microwave ther­
motherapy. We do not know whether epithelial cell damage is
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of any importance in the clinical response to microwave ther­
apy but it is certainly 1 of the 3 major cellular components of 
BPH. Interestingly, the variation of the PSA level within 1 
week after treatment was significantly different in the 2 
groups. Variation among the individual patients is high and 
reflects the different response of the individual prostate to 
microwave treatment, which we observed in previous stud­
ies. The kinetics of the PSA increase are outside the objec­
tives of our study but they certainly deserve attention in the 
future. The concept was confirmed in a recently conducted 
placebo controlled study.3
The key questions are why some patients achieve a higher 
intraprostatic temperature than  others and whether this is 
dependent on differing tissue architecture and blood supply 
in some prostates. Answering such questions will signifi­
cantly influence patient selection and the design of new 
treatm ent software in the future.
Analysis of different treatm ent parameters has shown that 
the amount of energy released during treatm ent differs sig­
nificantly in the 2 groups and more energy was delivered in 
responders compared to nonresponders. The observation was 
confirmed by the evaluation of 3 separate parameters: max­
imum power output during treatm ent, and total and average 
energy doses. Interestingly, the energy applied cannot be 
related to prostate size.
What happened to this greater amount of energy released 
into the prostate of patients who did well? A higher energy 
dose produced a higher urethral temperature, which is not 
evident when examining the peak urethral temperature 
achieved during treatment but it was clear if we note the 
maximum urethral temperature sustained for a t least 3 min­
utes. A higher urethral temperature has, of course, trig 
a greater number of urethral alarms, although the difference 
between the 2 groups was not significant because of the high 
variability of this parameter in different treatments (0 to 
150). Transient interruption of microwave emission seems 
not to be detrimental to treatm ent outcome or the total en­
ergy dose. Therefore, where is all this energy going? The flux 
of energy emitted by the microwave antenna passes through 
the prostate from the urethra to the rectum. As the irradia- 
tive energy is absorbed by tissue it is transformed into heat 
energy and the temperature increases. When temperatures 
increase vasodilatation occurs creating a heat sink, which 
may carry away significant amounts of heat. If irradiative 
energy is largely absorbed by pro static tissues then rectal 
temperature cannot increase (by lack of energy) and, conse­
quently, we expect fewer rectal alarms. Interestingly, this is 
what happened in the responder group. Lower temperatures 
were measured in the rectal wall of these patients and fewer 
alarms were recorded.
A higher energy dose with lower rectal temperature may be 
dependent on 2 different phenomena: either a higher energy 
absorption by the prostate tissue with a high intraprostatic 
temperature or a higher energy dissipation from a major 
blood supply with little temperature increase within the 
gland. Because patients with a higher energy deposition and 
lower rectal temperatures have a more successful treatment 
outcome, better energy deposition is more likely to be respon­
sible for fewer rectal alarms observed in responders.
CONCLUSIONS
None of the baseline parameters used within our study was 
able to define the ideal patient for and predict the result of
treatment. Changes in PSA levels and energy absorption of 
the prostate merely reflect the heterogeneity of the disease 
and variability of outcome to this treatm ent modality. Tissue 
architecture of the prostate gland and its relative blood sup­
ply might have a role in determining the outcome of micro­
wave heating.12 Investigation of possible correlations among 
these parameters might be important to understand the 
mechanism of therapeutic effect of microwave heating on 
BPH, resulting in more efficient heat induction of the pros­
tate.
Vincent Cabane assisted with the study.
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